Lupin Signs $50 Million Deal with Zentiva for Global Certolizumab Pegol Biosimilar Launch

Indian pharma major Lupin has signed a licensing and supply agreement with Czech company Zentiva to launch its biosimilar version of Certolizumab Pegol in multiple global markets.

Market Responsibilities Divided

Under the agreement, Lupin will develop, manufacture, and supply the drug. Zentiva will handle marketing and distribution in Europe and CIS countries. Lupin will take care of commercialisation in the US, Canada, and other parts of the world, excluding Australia, Japan, Brazil, the Philippines, and India.

Milestone Payments and Profit Sharing

Zentiva has agreed to pay Lupin up to $50 million in milestone payments. This includes an upfront payment of $10 million when the agreement was signed. Both companies will also share profits from the sale of the drug and invest together in its development.

Focus on Cost-Effective Biologics

Lupin stated that the deal doesn’t involve any acquisitions or related-party transactions. The company aims to increase its presence in international markets and improve access to affordable biosimilars for patients worldwide.

Lupin Share Price Reaction

Lupin share price was ₹1,930.00 as of 11:49 am on July 9, 2025, up 0.41% for the day. The stock opened at ₹1,933.40 and moved between an intraday high of ₹1,965.50 and a low of ₹1,927.70. The company has a market capitalisation of ₹88,150 crore, a P/E ratio of 26.92, and has traded between a 52-week high of ₹2,402.90 and a low of ₹1,766.05.

Also Read: CONCOR Shares in Focus After Release of Q1 Business Update: Domestic Volumes Rose 9%!

Conclusion

This partnership reflects Lupin’s focus on expanding its biosimilar portfolio and capturing new opportunities in global markets. By teaming up with Zentiva, Lupin hopes to strengthen its competitive edge and bring affordable treatments to more patients.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.